What is Entia?
Founded in 2015, Entia operates within the medical technology landscape, dedicating its efforts to improving the accessibility and efficiency of blood testing services. Based in the United Kingdom, the company's innovative approach aims to streamline diagnostic processes, potentially reducing turnaround times and enhancing patient care. Entia's focus on this critical area of healthcare positions it as a key player in the evolving medtech industry.
How much funding has Entia raised?
Entia has raised a total of $33.4M across 3 funding rounds:
Angel/Seed
$1.4M
Unspecified
$12M
Series A
$20M
Angel/Seed (2018): $1.4M with participation from Sussex Place Ventures
Unspecified (2021): $12M led by BGF, Parkwalk Advisors, and Sussex Place Ventures
Series A (2023): $20M supported by BGF
Key Investors in Entia
BGF
BGF, headquartered in London, United Kingdom, is the most active and influential investor in small and mid-sized businesses in the UK. An established and independent company, it supports a range of growing companies - early stage, growth stage, and quoted - across every region and sector of the economy.
Sussex Place Ventures
Sussex Place Ventures is an early stage venture capital investor that supports entrepreneurs developing enterprise software and strong patent-protectable deep technology. The company is independently managed and associated with the London Business School. They focus on helping businesses scale effectively without excessive funding. Their intended clients are entrepreneurs and businesses in the software and technology sectors.
Parkwalk Advisors
Parkwalk is a leading investor in university spinouts, focusing on deeptech innovations emerging from the UK's top universities. With over 15 years of experience, they bridge the gap between academic research and commercial success by providing funding, expertise, and networks to help these companies thrive. Their investment strategy spans the entire spinout lifecycle, supporting ventures in sectors such as AI, Quantum Computing, HealthTech, and CleanTech. Parkwalk offers tax-efficient investment opportunities for those looking to support groundbreaking science and technology.
What's next for Entia?
The recent major strategic investment in Entia signals a pivotal phase for the company, likely enabling significant expansion of its operational capabilities, further research and development, and broader market penetration. This infusion of capital, coupled with the company's established track record, suggests a strategic push towards scaling its solutions and solidifying its position in the competitive healthtech market. Entia is poised to leverage this backing to accelerate its mission of revolutionizing blood testing accessibility.
See full Entia company page
